Assertio Holdings, Inc. To Acquire Spectrum Pharmaceuticals, Inc. In All Stock And Cvr Transaction
04/25/23, 10:03 AM
Industry
pharmaceutical
biotechnology
manufacturing
Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio”), a specialty pharmaceutical company offering differentiated products to patients, and Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology, today announced that they have entered into a definitive agreement pursuant to which Assertio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights (“CVR”) transaction.
Company Info
Company info
Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.
Unlock Strategic Intelligence with Fundz
Access real-time funding updates, strategic shifts with FundzWatch™, exclusive Family Offices, and more — helping you close deals and seize opportunities faster.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.